Study guide
9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS)
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS)
Key Takeaways Explain This Topic AI
IARC Groups 1, 2A, 2B, and 3 express the strength of evidence that an agent is a human carcinogen; Group 4 (probably not carcinogenic to humans) has been retired and is no longer used.
EPA 2005 Guidelines descriptors are carcinogenic to humans, likely to be carcinogenic to humans, suggestive evidence of carcinogenic potential, inadequate information to assess carcinogenic potential, and not likely to be carcinogenic to humans.
Under EPA 2005, a mutagenic (DNA-reactive) mode of action defaults to linear low-dose extrapolation from a point of departure; a well-supported nonlinear MOA may support a nonlinear approach.
GHS Category 1A is known human carcinogenicity based largely on human evidence; 1B is presumed, based largely on animal evidence; Category 2 is suspected.
NTP Report on Carcinogens uses two listings—known to be a human carcinogen and reasonably anticipated to be a human carcinogen—and a non-listing is not a safety conclusion.
Last updated: September 2026
Why classification is still a hazard step
Cancer classification schemes sit inside hazard identification . They answer how strong the evidence is that an agent can cause cancer in humans (or, for GHS, how the evidence should be labeled for communication). They do not, by themselves, set a workplace limit, a cancer slope factor, or a drinking-water concentration. Those numbers require dose–response and exposure . Independent ExamFinch teaching in this section covers IARC , EPA’s 2005 Guidelines for Carcinogen Risk Assessment , GHS , and the NTP Report on Carcinogens (RoC) so you can tell the schemes apart on a DABT item. It is not an IARC, EPA, OSHA, or NTP product and does not claim official approval, review, or partnership with those bodies or with ABT.
A second examination skill is restraint on named chemicals . IARC evaluations are living documents. Use well-established examples you can defend— benzene and vinyl chloride are both IARC Group 1 —or speak generically. Do not invent a current Group for an agent whose Monograph you have not checked.
IARC Monograph groups
The International Agency for Research on Cancer evaluates agents (chemicals, mixtures, occupations, physical agents, biological agents) in Monographs. The evaluation is a hazard conclusion about cancer, not a quantitative risk estimate and not a recommendation to ban or permit use.
Current groups after the 2019 Preamble update:
Group 1 — Carcinogenic to humans. Sufficient evidence in humans, or a combination of sufficient evidence in animals plus strong mechanistic evidence in exposed humans, depending on the Preamble’s integration rules.
Group 2A — Probably carcinogenic to humans. Typically limited evidence in humans and sufficient evidence in animals, or other specified combinations including strong mechanistic data.
Group 2B — Possibly carcinogenic to humans. Typically limited human evidence or sufficient animal evidence that does not meet 2A, among other allowed combinations.
Group 3 — Not classifiable as to its carcinogenicity to humans. Evidence is inadequate in humans and inadequate or limited in animals, or the data do not fit a higher group. Group 3 is not a certificate of non-carcinogenicity.
Group 4 — Probably not carcinogenic to humans — has been retired. It is no longer part of the IARC scheme. Historically it was used extremely rarely (caprolactam was the classic occupant before later re-evaluation). If an item still lists Group 4 as a current option, the current answer is that the group is not used .
Benzene (leukemia, including acute myeloid leukemia, with bone-marrow toxicity as the organ story) and vinyl chloride (hepatic angiosarcoma as the highly specific pairing) are durable Group 1 teaching examples. Specificity in the Bradford Hill sense is unusually strong for vinyl chloride and angiosarcoma; benzene’s hematopoietic story is broader but equally well established as a human cancer hazard.
IARC does not issue potency (no slope factor, no “safe dose”). Two Group 1 agents can differ by orders of magnitude in carcinogenic potency. Classification strength is not the same variable as potency.
EPA 2005 Guidelines descriptors
The U.S. Environmental Protection Agency’s Guidelines for Carcinogen Risk Assessment (2005) describe weight-of-evidence descriptors that can be applied to a specified route and, when data allow, to all routes. The five descriptors are:
- Carcinogenic to humans
- Likely to be carcinogenic to humans
- Suggestive evidence of carcinogenic potential
- Inadequate information to assess carcinogenic potential
- Not likely to be carcinogenic to humans
Descriptors can be qualified by route . An agent may be “likely” by inhalation and “not likely” by the oral route if the database truly splits that way. “Not likely” is an affirmative WoE conclusion, not a missing-data bin; missing data belong under inadequate information .
EPA’s guidelines also include a mode of action (MOA) framework that changes how dose–response is done after the hazard descriptor is chosen:
Mutagenic (DNA-reactive) MOA. The default is linear extrapolation from a point of departure (POD) (often a BMD or LED associated with extra risk) down through the origin. The public-health rationale is that a single mutational event can contribute to cancer and that endogenous processes do not provide a practical threshold you can defend for regulation.
Nonlinear MOA. If a well-supported MOA is cytotoxicity with regenerative proliferation, or another threshold-type key event, EPA may use a nonlinear (reference-dose-like or margin-of-exposure) approach below the POD.
Unknown or mixed MOA. Linear methods are often retained as a health-protective default when a mutagenic MOA cannot be reasonably ruled out.
Do not confuse the descriptor (words about evidence strength) with the extrapolation method (linear versus nonlinear). A “likely” carcinogen with a mutagenic MOA still uses linear low-dose methods in the default EPA logic. IARC’s Group number does not dictate EPA’s math.
GHS carcinogen categories
The UN Globally Harmonized System (GHS) classifies carcinogens for hazard communication (labels and safety data sheets):
Category 1 — Known or presumed human carcinogens.
1A — Known , based largely on human evidence.
1B — Presumed , based largely on animal evidence.
Category 2 — Suspected human carcinogens , when human and animal evidence is not sufficiently convincing for Category 1.
GHS is a labeling scheme with specified criteria, not a cancer-potency assessment. A 1B label can trigger the same communication duties as 1A in many jurisdictions even though the evidence base differs. Do not translate GHS 1B as “IARC Group 3” or as EPA “not likely.” The mapping is many-to-many, not one-to-one.
NTP Report on Carcinogens
The U.S. National Toxicology Program Report on Carcinogens is a congressionally mandated listing of substances that are:
Known to be a human carcinogen , or
Reasonably anticipated to be a human carcinogen.
“Known” requires sufficient human evidence (or specified equivalent integration). “Reasonably anticipated” typically rests on sufficient animal evidence or a combination of limited human evidence and other data, depending on the listing criteria in force for that RoC edition. Absence from the RoC is not a conclusion of safety. Many agents have never been reviewed. Benzene and vinyl chloride are in the “known” teaching set alongside their IARC Group 1 evaluations; use them as examples of concordant high-confidence listings , not as a claim that every scheme always agrees on every chemical.
Agencies can disagree on agents that are still under scientific debate. That disagreement is a feature of different evidence rules, different default assumptions, and different jobs (research evaluation versus regulation versus labeling). It is not proof that one scheme is “the real IARC.” On an item, name the scheme the stem asks for.
Scheme Highest-confidence cancer hazard Intermediate Inadequate / lowest
IARC Monographs Group 1 (carcinogenic to humans) Group 2A (probably), Group 2B (possibly) Group 3 (not classifiable); Group 4 retired
EPA 2005 Guidelines Carcinogenic to humans Likely; suggestive evidence Inadequate information; not likely
GHS Category 1A (known, human evidence) Category 1B (presumed, animal evidence) Category 2 (suspected); unclassified if criteria not met
NTP RoC Known to be a human carcinogen Reasonably anticipated to be a human carcinogen Not listed (often never reviewed—not a safety finding)
Read the table as related vocabularies , not as a conversion chart. IARC 2B is not identical to EPA “suggestive.” GHS 1B is not identical to NTP “reasonably anticipated,” even when they often land on the same famous chemicals.
Scenario
A stem gives sufficient human epidemiologic evidence of leukemia in benzene-exposed workers, supporting animal data, and a DNA-reactive metabolite story. IARC Group 1 , EPA carcinogenic to humans , GHS 1A , and NTP known are the concordant high-confidence labels. EPA’s linear default still applies for low-dose extrapolation if the MOA is treated as mutagenic. None of those labels is a PEL or an IRIS slope factor by itself.
A second stem has only limited human evidence and sufficient animal tumors, without strong human mechanistic data. IARC may land in 2A or 2B depending on the full Preamble integration; EPA may land on likely or suggestive ; GHS may be 1B or 2 . Forcing all four schemes onto one letter is the error.
A third stem asks whether Group 4 means “proven safe.” The current answer is that Group 4 is retired , and even historically it was not a general “safe chemical” bin.
Traps
Treating Group 3 or “inadequate information” as proof of non-carcinogenicity.
Using Group 4 as if it were still an active IARC category.
Equating IARC group, EPA descriptor, GHS category, and NTP listing as interchangeable codes.
Letting an IARC group choose linear versus nonlinear EPA math.
Inventing a current IARC Group for a chemical whose Monograph you have not verified—stay with benzene, vinyl chloride, or generic wording.